Astragaloside IV treatment is associated with caecal microbial differences without an observed reduction in high-choline-associated plasma TMAO: a pilot mouse study

Background Astragaloside IV (AS-IV) has reported anti-atherosclerotic effects and may alter the gut microbiota, but its relationship to the microbial choline–trimethylamine (TMA)–trimethylamine-N-oxide (TMAO) axis remains unclear. Methods In this exploratory pilot, twelve male C57BL/6J mice were assigned to Control, 1% choline (Model), or 1% choline plus AS-IV (40 mg/kg/day) groups (n = 4 each) for 28 days. Caecal 16S rRNA profiles, plasma choline/TMA/TMAO, and a sensitivity-tested CutC docking analysis were evaluated. The four mice in each group shared one cage, so cage and treatment were completely confounded. Results Bray–Curtis community composition differed among groups (PERMANOVA R2 = 0.619, P = 0.001), although the small sample and one-cage-per-group design preclude population-level or causal inference. High-choline exposure was associated with a 10.7-fold higher mean plasma TMAO than Control (668.3 vs. 62.3 ng/mL); mean TMAO remained high with AS-IV (709.8 ng/mL; AS-IV vs. Model P = 1.000). TMA and choline showed similar group patterns, but several measurements exceeded the vendor-reported quantification range and are exploratory. Taxonomic functional predictions were hypothesis-generating only. Docking scores for AS-IV and cycloastragenol were strongly dependent on search-box size and were not interpreted as evidence for or against CutC inhibition. Conclusion AS-IV treatment was associated with a different caecal microbial composition without an observed reduction in high-choline-associated plasma TMAO. These findings generate hypotheses but require replication in a powered, multi-cage study including both sexes and direct functional measurements.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-12
DOI
https://doi.org/10.3389/fphar.2026.1955228
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Astragaloside IV treatment is associated with caecal microbial differences without an observed reduction in high-choline-associated plasma TMAO: a pilot mouse study

Zhou Qingyun, Yanling Zhou, Xiaolong Shu
Frontiers in Pharmacology
Gut microbiota and health
article

Astragaloside IV treatment is associated with caecal microbial differences without an observed reduction in high-choline-associated plasma TMAO: a pilot mouse study

Zhou Qingyun, Yanling Zhou, Xiaolong Shu
article en

Abstract

Background Astragaloside IV (AS-IV) has reported anti-atherosclerotic effects and may alter the gut microbiota, but its relationship to the microbial choline–trimethylamine (TMA)–trimethylamine-N-oxide (TMAO) axis remains unclear. Methods In this exploratory pilot, twelve male C57BL/6J mice were assigned to Control, 1% choline (Model), or 1% choline plus AS-IV (40 mg/kg/day) groups (n = 4 each) for 28 days. Caecal 16S rRNA profiles, plasma choline/TMA/TMAO, and a sensitivity-tested CutC docking analysis were evaluated. The four mice in each group shared one cage, so cage and treatment were completely confounded. Results Bray–Curtis community composition differed among groups (PERMANOVA R2 = 0.619, P = 0.001), although the small sample and one-cage-per-group design preclude population-level or causal inference. High-choline exposure was associated with a 10.7-fold higher mean plasma TMAO than Control (668.3 vs. 62.3 ng/mL); mean TMAO remained high with AS-IV (709.8 ng/mL; AS-IV vs. Model P = 1.000). TMA and choline showed similar group patterns, but several measurements exceeded the vendor-reported quantification range and are exploratory. Taxonomic functional predictions were hypothesis-generating only. Docking scores for AS-IV and cycloastragenol were strongly dependent on search-box size and were not interpreted as evidence for or against CutC inhibition. Conclusion AS-IV treatment was associated with a different caecal microbial composition without an observed reduction in high-choline-associated plasma TMAO. These findings generate hypotheses but require replication in a powered, multi-cage study including both sexes and direct functional measurements.

Frontiers in PharmacologyVol. 17
Ningbo Medical Center Lihuili Hospital (CN), Chengdu University of Traditional Chinese Medicine (CN)
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon